Source: Pharmacy Times articles
A new biosimilar to ustekinumab (Stelara) has been approved by the FDA, further expanding treatment options for patients with immune conditions such as plaque psoriasis and psoriatic arthritis.
Read More
by MM360 Staff | May 28, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
A new biosimilar to ustekinumab (Stelara) has been approved by the FDA, further expanding treatment options for patients with immune conditions such as plaque psoriasis and psoriatic arthritis.
Read More